A pyrazolopyridine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof exhibits strong EP1 receptor antagonism. Thus, the derivative or the pharmacologically acceptable salt thereof is useful as a therapeutic drug or a prophylactic drug for lower urinary tract symptoms (LUTS), and particularly overactive bladder syndrome (OABs), and is also useful for the treatment, prophylaxis, or suppression of various pathoses involving the EP1 receptor, such as inflammatory diseases, pain diseases, osteoporosis, and cancer. [A is a benzene ring, etc.； Y1 is a C1-6 alkylene； R1 is -C(=O)-OZ1, etc.； Z1 is H, etc.； R2 is a branched-chain C3-6 alkyl group, etc.； R3 is H, etc.； R4 is a hydrogen atom, etc.； and R5 is a hydrogen atom, etc.]
